Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles

Journal of Infection and Chemotherapy

Volumn 20, Issue 6, 2014, Pages 375-379

  Koyama, Kazuya ^a   Ohshima, Nobuharu ^a   Suzuki, Junko ^a   Kawashima, Masahiro ^a   Takeda, Keita ^a   Ando, Takahiro ^a   Sato, Ryota ^a   Nagai, Hideaki ^a   Matsui, Hirotoshi ^a   Ohta, Ken ^a  

^a TOKYO NATIONAL HOSPITAL   (Japan)

Author keywords

Anti Aspergillus antibody; Chronic pulmonary aspergillosis; Maintenance treatment; Recurrence; Treatment duration; Triazole

Indexed keywords

AMPHOTERICIN B; ANTIBODY; ASPERGILLUS ANTIBODY; ITRACONAZOLE; MICAFUNGIN; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE; ANTIFUNGAL AGENT;

ADULT; AGED; ARTICLE; CHRONIC PULMONARY ASPERGILLOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFECTION RISK; LUNG ASPERGILLOSIS; LUNG LOBE; MALE; MEDICAL RECORD REVIEW; PRESCRIPTION; RECURRENCE RISK; RECURRENT INFECTION; RELAPSE; RISK FACTOR; SEROCONVERSION; THORAX RADIOGRAPHY; TREATMENT DURATION; MAINTENANCE CHEMOTHERAPY; MICROBIOLOGY; MIDDLE AGED; PULMONARY ASPERGILLOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; SUBSTANCE WITHDRAWAL SYNDROME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PULMONARY ASPERGILLOSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SUBSTANCE WITHDRAWAL SYNDROME; TRIAZOLES;

EID: 84903698948     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2014.02.003     Document Type: Article

References (18)

1. Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, et al. An official American thoracic society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011;183: 96-128.
2. Yoshida K, Kurashima A, Kamei K, Oritsu M, Ando T, Yamamoto T, et al. Efficacy and safety of short- and long-term treatment of itraconazole on chronic necrotizing pulmonary aspergillosis in multicenter study. J Infect Chemother 2012;18: 378-85.
3. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis 2008;46: 327-60.
4. van Rens MT, Vernooy-Jeras R, Merton-de Ridder M, van Velzen-Blad H, van den Bosch JM. Detection of immunoglobulins G and A to Aspergillus fumigatus by immunoblot analysis for monitoring Aspergillus-induced lung diseases. Eur Respir J 1998;11: 1274-80.
5. Tomee JF, van der Werf TS, Latge JP, Koeter GH, Dubois AE, Kauffman HF. Serologic monitoring of disease and treatment in a patient with pulmonary aspergilloma. Am J Respir Crit Care Med 1995;151: 199-204.
6. Campbell MJ, Clayton YM. Bronchopulmonary aspergillosis. A correlation of the clinical and laboratory findings in 272 patients investigated for bronchopulmonary aspergillosis. Am Rev Respir Dis 1964;89: 186-96.
7. Coleman RM, Kaufman L. Use of the immunodiffusion test in the serodiagnosis of aspergillosis. Appl Microbiol 1972;23: 301-8.
8. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990;23: 607-14.
9. Ohba H, Miwa S, Shirai M, Kanai M, Eifuku T, Suda T, et al. Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med 2012;106: 724-9.
10. Jhun BW, Jeon K, Eom JS, Lee JH, Suh GY, Kwon OJ, et al. Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis. Med Mycol 2013;51: 811-7.
11. Cadranel J, Philippe B, Hennequin C, Bergeron A, Bergot E, Bourdin A, et al. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis 2012;31: 3231-9.
12. Campbell JH, Winter JH, Richardson MD, Shankland GS, Banham SW. Treatment of pulmonary aspergilloma with itraconazole. Thorax 1991;46: 839-41.
13. Lebeau B, Pelloux H, Pinel C, Michallet M, Gout JP, Pison C, et al. Itraconazole in the treatment of aspergillosis: a study of 16 cases. Mycoses 1994;37: 171-9.
14. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009;15: 1068-76.
15. van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ, et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis 2011;17: 1846-54.
16. Tashiro M, Izumikawa K, Hirano K, Ide S, Mihara T, Hosogaya N, et al. Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus. Antimicrob Agents Chemother 2012;56:4870-5.
17. Burgel PR, Baixench MT, Amsellem M, Audureau E, Chapron J, Kanaan R, et al. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother 2012;56:869-74.
18. Smith NL, Denning DW. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 2011;37: 865-72.